The use of the fusion protein RGD-HSA-TIMP2 as a tumor targeting imaging probe for SPECT and PET.

[1]  Xiaoyuan Chen,et al.  RGD-Human Serum Albumin Conjugates as Efficient Tumor Targeting Probes , 2009, Molecular imaging.

[2]  Chenjie Xu,et al.  PET/MRI Dual-Modality Tumor Imaging Using Arginine-Glycine-Aspartic (RGD)–Conjugated Radiolabeled Iron Oxide Nanoparticles , 2008, Journal of Nuclear Medicine.

[3]  Young Joo Kim,et al.  Preparation of a Promising Angiogenesis PET Imaging Agent: 68Ga-Labeled c(RGDyK)–Isothiocyanatobenzyl-1,4,7-Triazacyclononane-1,4,7-Triacetic Acid and Feasibility Studies in Mice , 2008, Journal of Nuclear Medicine.

[4]  Paul A Dayton,et al.  A stimulus-responsive contrast agent for ultrasound molecular imaging. , 2008, Biomaterials.

[5]  Sanjiv S. Gambhir,et al.  Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature , 2007, Journal of Nuclear Medicine.

[6]  Jeong-Yoon Kim,et al.  A biologically active angiogenesis inhibitor, human serum albumin-TIMP-2 fusion protein, secreted from Saccharomyces cerevisiae. , 2007, Protein expression and purification.

[7]  Young-Seung Kim,et al.  Evaluation of a 99mTc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin αvβ3-Positive Breast Cancer , 2007 .

[8]  Shuang Liu.  Radiolabeled Multimeric Cyclic RGD Peptides as Integrin αvβ3 Targeted Radiotracers for Tumor Imaging , 2006 .

[9]  Veerle Kersemans,et al.  In vivo characterization of 123/125I-2-iodo-L-phenylalanine in an R1M rhabdomyosarcoma athymic mouse model as a potential tumor tracer for SPECT. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  W. Stetler-Stevenson,et al.  TIMP-2: an endogenous inhibitor of angiogenesis. , 2005, Trends in molecular medicine.

[11]  R. Moats,et al.  In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts , 2004, Cancer Research.

[12]  Rex Moats,et al.  18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. , 2004, Nuclear medicine and biology.

[13]  P. Wingfield,et al.  TIMP-2 Mediated Inhibition of Angiogenesis An MMP-Independent Mechanism , 2003, Cell.

[14]  R. Hynes.  A reevaluation of integrins as regulators of angiogenesis , 2002, Nature Medicine.

[15]  Y. Okada,et al.  Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma. , 2001, Journal of neurosurgery.

[16]  M. Schwaiger,et al.  Carbohydrate Derivatives for Use in Drug Design: Cyclicαv-Selective RGD Peptides , 2000 .

[17]  Y. DeClerck.  Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. , 2000, European journal of cancer.

[18]  Horst Kessler,et al.  Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting , 1999 .

[19]  S. Weiss,et al.  Matrix Metalloproteinases Regulate Neovascularization by Acting as Pericellular Fibrinolysins , 1998, Cell.

[20]  J. Foidart,et al.  Inhibition of stromal matrix metalloproteases: Effects on breast‐tumor promotion by fibroblasts , 1998, International journal of cancer.

[21]  H. Krell,et al.  β1 Integrin Is Essential for Teratoma Growth and Angiogenesis , 1997, The Journal of cell biology.

[22]  D. Gomez,et al.  Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. , 1997, European journal of cell biology.

[23]  M. Brechbiel,et al.  In vitro and in vivo evaluation of structure-stability relationship of 111In- and 67Ga-labeled antibody via 1B4M or C-NOTA chelates. , 1997, Nuclear medicine and biology.

[24]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[25]  C. Meares,et al.  Synthesis of novel 1,4,7-triazacyclononane-N,N',N"-triacetic acid derivatives suitable for protein labeling. , 1992, Bioconjugate chemistry.

[26]  R. Kizek,et al.  Matrix metalloproteinases. , 2010, Current medicinal chemistry.

[27]  Xiaoyuan Chen,et al.  Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. , 2007, Bioconjugate chemistry.

[28]  D. Parker,et al.  RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker alpha(v) beta3 integrin with MRT, mapping. , 2007 .

[29]  Shuang Liu.  Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. , 2006, Molecular pharmaceutics.

[30]  R. Béliveau,et al.  Expression of matrix metalloproteinases and their inhibitors in human brain tumors , 2004, Clinical & Experimental Metastasis.

[31]  Grietje Molema,et al.  Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics. , 2002, Bioconjugate chemistry.

[32]  M. Schwaiger,et al.  Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  M. Lim,et al.  The role of metalloproteinases and their inhibitors in hematological disorders. , 1996, Critical reviews in oncogenesis.